

REMARKS

Claims 1-6 and 8-11 remain in the application. Applicants have withdrawn claims 7 and 12-17 from consideration but reserve the right to pursue these claims in a divisional application. Applicants reserve the right to pursue the unelected subject matter of claims 1 through 11 in divisional applications.

Claims 1-17 stand rejected under 35 U.S.C. 112, second paragraph, as being indefinite for the terms, "pharmaceutically acceptable salts, esters, amides and prodrugs." Claims 1-17 also stand rejected under 35 U.S.C. 112, first paragraph, for not being enabling for the term "prodrugs." Applicants have amended to the claims to remove the terms, "esters, amides and prodrugs."

Applicants respectfully submit that the remaining subject matter in pending claims 1-6 and 8-11 are in condition for allowance and respectfully request the Examiner to allow these claims to pass to issuance.

Respectfully submitted,

Date: November 6, 2006

/Wendy L. Hsu/
Wendy L. Hsu
Attorney For Applicants
Registration No. 42,794

Pfizer Inc.
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 526-4652
Fax: (858) 678-8233